DGIdb - SLC18A2 Gene Record

SLC18A2 6571 Druggable Genome

Alternate Names:

6571
SOLUTE CARRIER FAMILY 18 MEMBER A2
SLC18A2
SVAT
SVMT
VAT2
VMAT2
193001
10935
ENSG00000165646
OTTHUMG00000019121
1012
Q05940
Vesicular monoamine transporter 2
BE0000118
SYNAPTIC VESICULAR AMINE TRANSPORTER (MONOAMINE TRANSPORTER) (VESICULAR AMINE TRANSPORTER 2) (VAT2) (SOLUTE CARRIER FAMILY 18, MEMBER 2). [SOURCE:UNIPROT/SWISSPROT;ACC:Q05940]
VMAT2_HUMAN
SOLUTE CARRIER FAMILY 18 MEMBER 2
SYNAPTIC VESICLE AMINE TRANSPORTER
MONOAMINE TRANSPORTER
Vesicular amine transporter 2
Synaptic vesicular amine transporter
PA325
T48873
BE0008661
Q99870

Gene Info:

GuideToPharmacology Gene Category Name	SLC18 family of vesicular amine transporters
GuideToPharmacology Gene Category ID	193
Human Readable Name	DRUGGABLE GENOME
Target Main Class	Transporters
Target Subclass	SLC
Transmembrane Helix Count	12
Target Subclass	SLC18
Target Subclass	MFS
Target Class	Transporters
Target Subclass	TC:2.A.1.2.29
Gene Biotype	PROTEIN_CODING

(8 More Sources)

Gene Categories: Category Details

TRANSPORTER
DRUGGABLE GENOME

Publications:

Biezonski et al., 2010, Effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin transporter and vesicular monoamine transporter 2 protein and gene expression in rats: implications for MDMA neurotoxicity., J. Neurochem.
Hansen et al., 2002, Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity., J. Pharmacol. Exp. Ther.
Fleckenstein et al., 2007, New insights into the mechanism of action of amphetamines., Annu. Rev. Pharmacol. Toxicol.
Sulzer et al., 1995, Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport., J. Neurosci.
Yasumoto et al., 2009, Inhibitory effect of selective serotonin reuptake inhibitors on the vesicular monoamine transporter 2., Neurosci. Lett.
Horton et al., 2011, meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release., J. Pharmacol. Exp. Ther.
Sulzer et al., 2005, Mechanisms of neurotransmitter release by amphetamines: a review., Prog. Neurobiol.
Tiwari AK et al., 2013, Analysis of 34 candidate genes in bupropion and placebo remission., Int J Neuropsychopharmacol
FORD et al., 1958, Rauwolfia toxicity in the treatment of hypertension; comparative toxicity of reserpine and alseroxylon., Postgrad Med
Mandela et al., Reserpine-induced reduction in norepinephrine transporter function requires catecholamine storage vesicles., Neurochem. Int.
Erickson et al., 1992, Expression cloning of a reserpine-sensitive vesicular monoamine transporter., Proc. Natl. Acad. Sci. U.S.A.
SCHLAGEL et al., 1957, Rauwolfia hypotension. II. Action of the alseroxylon alkaloids and epinephrine on the carotid pressoreceptors., J Am Pharm Assoc Am Pharm Assoc
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Sievert et al., 2007, Specific derivatization of the vesicle monoamine transporter with novel carrier-free radioiodinated reserpine and tetrabenazine photoaffinity labels., Anal. Biochem.
Naudon et al., 1995, Time-course of modifications elicited by reserpine on the density and mRNA synthesis of the vesicular monoamine transporter, and on the density of the membrane dopamine uptake complex., Synapse
Fulton et al., 1976, Comparison of the effectiveness of deserpidine, reserpine, and alpha-methyltyrosine on brain biogenic amines., Fed. Proc.
Loeffler et al., 1979, Antibody specificity studies for reserpine, its metabolites, and synthetic reserpine congeners: radioimmunoassay., J Pharm Sci
Gros et al., 2010, Directed evolution reveals hidden properties of VMAT, a neurotransmitter transporter., J. Biol. Chem.
Kim et al., 2009, Dopamine signaling is required for depolarization-induced slow current in cerebellar Purkinje cells., J. Neurosci.
Goland et al., 2009, 11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls., J. Nucl. Med.
Wimalasena, 2011, Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry., Med Res Rev
Zheng et al., 2006, Vesicular monoamine transporter 2: role as a novel target for drug development., AAPS J
Erickson et al., 1996, Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter., Proc. Natl. Acad. Sci. U.S.A.
Heal et al., 2013, Amphetamine, past and present--a pharmacological and clinical perspective., J. Psychopharmacol. (Oxford)
Teng et al., 1998, Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine., J. Neurochem.
Eiden et al., 2011, VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse., Ann. N. Y. Acad. Sci.
Henry et al., 1998, The vesicular monoamine transporter: from chromaffin granule to brain., Neurochem. Int.
Docherty, 2008, Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA)., Br. J. Pharmacol.
Valdivia et al., 2004, Pharmacological analysis of the mechanisms involved in the tachycardic and vasopressor responses to the antimigraine agent, isometheptene, in pithed rats., Life Sci.
Parker et al., 1988, Comparative effects of amphetamine, phenylethylamine and related drugs on dopamine efflux, dopamine uptake and mazindol binding., J. Pharmacol. Exp. Ther.
Gonzalez AM et al., 1994, Synaptic vesicular monoamine transporter expression: distribution and pharmacologic profile., Brain Res Mol Brain Res
Braselmann S et al., 2006, R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation., J Pharmacol Exp Ther
Rolf MG et al., 2015, In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib., Pharmacol Res Perspect

ISOMETHEPTENE SLC18A2

Interaction Score: 4.18

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
15094323 7751968 3129549 15955613

Sources:
DrugBank
TETRABENAZINE SLC18A2

Interaction Score: 4.01

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name tetrabenazine,Nitoman

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

PMIDs:
20007701 19571144 19223416 11752352 20135628 17233532

Sources:
TEND TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions
DESERPIDINE SLC18A2

Interaction Score: 3.34

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

Direct Interaction yes

PMIDs:
20176067 11134 574544 1438304 17559790 8525459

Sources:
DrugBank ChemblInteractions
VALBENAZINE TOSYLATE SLC18A2

Interaction Score: 3.34

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name NBI-98854

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial TTD
DEUTETRABENAZINE SLC18A2

Interaction Score: 2.51

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True

PMIDs:
None found

Sources:
TTD DrugBank GuideToPharmacology
ALSEROXYLON SLC18A2

Interaction Score: 2.23

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
13505370 13438725 11752352 17139284 17016423

Sources:
TEND TdgClinicalTrial TTD
PROPYLHEXEDRINE SLC18A2

Interaction Score: 1.67

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18500382 15955613

Sources:
DrugBank
ALKAVERVIR SLC18A2

Interaction Score: 1.67

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
VALBENAZINE SLC18A2

Interaction Score: 1.67

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

PMIDs:
None found

Sources:
DrugBank ChemblInteractions
DEXTROAMPHETAMINE SLC18A2

Interaction Score: 1.04

Interaction Types & Directionality:

inducer (activating)

inhibitor (inhibitory)

Interaction Info:

Trial Name SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR

Novel drug target Established target

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

PMIDs:
7751968 15955613

Sources:
TdgClinicalTrial DrugBank ChemblInteractions
RESERPINE SLC18A2

Interaction Score: 0.96

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

Direct Interaction yes

Trial Name -

PMIDs:
13505370 20176067 1438304 13438725 11752352 17139284 17016423 17559790 8525459

Sources:
TEND TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions
MIDOMAFETAMINE SLC18A2

Interaction Score: 0.95

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
20002520 11861820

Sources:
TTD DrugBank
CHEMBL126506 SLC18A2

Interaction Score: 0.84

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
17209801 9587917 15955613

Sources:
DrugBank
LOBELINE SLC18A2

Interaction Score: 0.84

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Established target

Trial Name Lobeline

PMIDs:
None found

Sources:
TdgClinicalTrial TTD
BENZPHETAMINE HYDROCHLORIDE SLC18A2

Interaction Score: 0.84

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
LISDEXAMFETAMINE DIMESYLATE SLC18A2

Interaction Score: 0.84

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

Direct Interaction yes

Trial Name Vyvanse

PMIDs:
None found

Sources:
TdgClinicalTrial ChemblInteractions
PARA-METHOXYAMPHETAMINE SLC18A2

Interaction Score: 0.72

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
20002520 11861820

Sources:
DrugBank
BENZPHETAMINE SLC18A2

Interaction Score: 0.67

Interaction Types & Directionality:

inducer (activating)

Interaction Info:

PMIDs:
7751968

Sources:
DrugBank
AMPHETAMINE SLC18A2

Interaction Score: 0.58

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name C105, levo-amphetamine sulfate

Novel drug target Established target

Trial Name SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR

PMIDs:
23539642 7751968 9648873 21272013 15955613

Sources:
TdgClinicalTrial DrugBank
MAZINDOL SLC18A2

Interaction Score: 0.56

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7912402

Sources:
DrugBank
DEXTROAMPHETAMINE ADIPATE SLC18A2

Interaction Score: 0.56

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
DEXTROAMPHETAMINE SULFATE SLC18A2

Interaction Score: 0.56

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
EPHEDRA SLC18A2

Interaction Score: 0.51

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
17209801 9587917 15955613

Sources:
DrugBank
METHAMPHETAMINE SLC18A2

Interaction Score: 0.45

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name low dose intravenous methamphetamine

Novel drug target Established target

PMIDs:
17209801 7751968 19429089 21177475 15955613

Sources:
TdgClinicalTrial DrugBank
NOMIFENSINE SLC18A2

Interaction Score: 0.42

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7912402

Sources:
DrugBank
RESCINNAMINE SLC18A2

Interaction Score: 0.33

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
HISTAMINE SLC18A2

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7912402

Sources:
DrugBank
BUPROPION SLC18A2

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22947179

Sources:
PharmGKB
SEROTONIN SLC18A2

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7912402

Sources:
DrugBank
NOREPINEPHRINE SLC18A2

Interaction Score: 0.12

Interaction Types & Directionality:

binder

Interaction Info:

PMIDs:
8643547

Sources:
DrugBank
DOPAMINE SLC18A2

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7912402

Sources:
DrugBank
KETANSERIN SLC18A2

Interaction Score: 0.08

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
GuideToPharmacology
HALOPERIDOL SLC18A2

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7912402

Sources:
DrugBank
FOSTAMATINIB SLC18A2

Interaction Score: 0.02

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
16946104 26516587

Sources:
DrugBank

Ensembl: ENSG00000165646
- Version: 101_38
Alternate Names:

SLC18A2 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
TdgClinicalTrial: Q05940
- Version: January-2014
Alternate Names:

SLC18A2 Gene Symbol

Gene Info:

Target Class Transporters

Target Subclass TC:2.A.1.2.29

Publications:
TEND: Q05940
- Version: 01-August-2011
Alternate Names:

ENSG00000165646 Ensembl Gene Id

6571 Entrez Gene Id

SLC18A2 Gene Symbol

Gene Info:

Target Main Class Transporters

Target Subclass SLC

Transmembrane Helix Count 12

Publications:

RussLampel: ENSG00000165646

Version: 26-July-2011

Alternate Names:

SLC18A2 Display Id

SYNAPTIC VESICULAR AMINE TRANSPORTER (MONOAMINE TRANSPORTER) (VESICULAR AMINE TRANSPORTER 2) (VAT2) (SOLUTE CARRIER FAMILY 18, MEMBER 2). [SOURCE:UNIPROT/SWISSPROT;ACC:Q05940] Description

ENSG00000165646 Ensembl Gene Id

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:

GuideToPharmacology: 6571
- Version: 29-September-2020
Alternate Names:

10935 HUGO Gene ID

10935 HUGO Gene Symbol

solute carrier family 18 member A2 HUGO Gene Name

Gene Info:

GuideToPharmacology Gene Category Name SLC18 family of vesicular amine transporters

GuideToPharmacology Gene Category ID 193

Gene Categories:

TRANSPORTER

Publications:

PharmGKB: SLC18A2

Version: 18-August-2020

Alternate Names:

PA325 PharmGKB ID

Gene Info:

Publications:

Mas S et al., 2016, Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes., Pharmacogenomics J

Tiwari AK et al., 2013, Analysis of 34 candidate genes in bupropion and placebo remission., Int J Neuropsychopharmacol

DrugBank: BE0008661

Version: 5.1.7

Alternate Names:

VMAT2 DrugBank Gene Name

Q99870 UniProt Accession

Gene Info:

Publications:

Heal et al., 2013, Amphetamine, past and present--a pharmacological and clinical perspective., J. Psychopharmacol. (Oxford)

Braselmann S et al., 2006, R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation., J Pharmacol Exp Ther

Rolf MG et al., 2015, In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib., Pharmacol Res Perspect

DrugBank: BE0000118

Version: 5.1.7

Alternate Names:

SLC18A2 DrugBank Gene Name

Q05940 UniProt Accession

6571 Entrez Gene Id

Gene Info:

Publications:

Mandela et al., Reserpine-induced reduction in norepinephrine transporter function requires catecholamine storage vesicles., Neurochem. Int.

Erickson et al., 1992, Expression cloning of a reserpine-sensitive vesicular monoamine transporter., Proc. Natl. Acad. Sci. U.S.A.

Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.

HingoraniCasas: ENSG00000165646
- Version: 31-May-2017
Alternate Names:

ENSG00000165646 Gene Symbol

SLC18A2 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
ChemblInteractions: SVMT
- Version: chembl_23
Alternate Names:

VMAT2 GENE_SYMBOL

SLC18A2 GENE_SYMBOL

Synaptic vesicular amine transporter UNIPROT

Gene Info:

Publications:
Pharos: SLC18A2
- Version: 03-September-2020
Alternate Names:

Synaptic vesicular amine transporter Gene Name

Q05940 UniProt ID

Gene Info:

Gene Categories:

TRANSPORTER

Publications:
TTD: Synaptic vesicle amine transporter
- Version: 2020.06.01
Alternate Names:

SLC18A2 TTD Gene Abbreviation

T48873 TTD Target ID

Gene Info:

Publications:

Novel drug target	Established target
Trial Name	tetrabenazine,Nitoman
Mechanism of Interaction	Synaptic vesicular amine transporter inhibitor

Mechanism of Interaction	Synaptic vesicular amine transporter inhibitor
Direct Interaction	yes

Specific Action of the Ligand	Inhibition
Endogenous Drug?	False
Direct Interaction?	True

Trial Name	SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR
Novel drug target	Established target
Mechanism of Interaction	Synaptic vesicular amine transporter inhibitor

Trial Name	C105, levo-amphetamine sulfate
Novel drug target	Established target
Trial Name	SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR

Trial Name	low dose intravenous methamphetamine
Novel drug target	Established target

ENSG00000165646	Ensembl Gene Id
6571	Entrez Gene Id
SLC18A2	Gene Symbol

SLC18A2	Display Id
SYNAPTIC VESICULAR AMINE TRANSPORTER (MONOAMINE TRANSPORTER) (VESICULAR AMINE TRANSPORTER 2) (VAT2) (SOLUTE CARRIER FAMILY 18, MEMBER 2). [SOURCE:UNIPROT/SWISSPROT;ACC:Q05940]	Description
ENSG00000165646	Ensembl Gene Id

10935	HUGO Gene ID
10935	HUGO Gene Symbol
solute carrier family 18 member A2	HUGO Gene Name

SLC18A2	DrugBank Gene Name
Q05940	UniProt Accession
6571	Entrez Gene Id

antagonist (inhibitory)
inhibitor (inhibitory)

inducer (activating)
inhibitor (inhibitory)

VMAT2	GENE_SYMBOL
SLC18A2	GENE_SYMBOL
Synaptic vesicular amine transporter	UNIPROT

Synaptic vesicular amine transporter	Gene Name
Q05940	UniProt ID

SLC18A2 Gene Record

SLC18A2 6571 Druggable Genome

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 15094323 7751968 3129549 15955613

Sources: DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name tetrabenazine,Nitoman Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

PMIDs: 20007701 19571144 19223416 11752352 20135628 17233532

Sources: TEND TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Synaptic vesicular amine transporter inhibitor Direct Interaction yes

PMIDs: 20176067 11134 574544 1438304 17559790 8525459

Sources: DrugBank ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info: Trial Name NBI-98854 Novel drug target Established target

PMIDs: None found

Sources: TdgClinicalTrial TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? True

PMIDs: None found

Sources: TTD DrugBank GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 13505370 13438725 11752352 17139284 17016423

Sources: TEND TdgClinicalTrial TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18500382 15955613

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

PMIDs: None found

Sources: DrugBank ChemblInteractions

Interaction Types & Directionality: inducer (activating) inhibitor (inhibitory)

Interaction Info: Trial Name SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR Novel drug target Established target Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

PMIDs: 7751968 15955613

Sources: TdgClinicalTrial DrugBank ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Synaptic vesicular amine transporter inhibitor Direct Interaction yes Trial Name -

PMIDs: 13505370 20176067 1438304 13438725 11752352 17139284 17016423 17559790 8525459

Sources: TEND TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 20002520 11861820

Sources: TTD DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 17209801 9587917 15955613

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info: Novel drug target Established target Trial Name Lobeline

PMIDs: None found

Sources: TdgClinicalTrial TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Synaptic vesicular amine transporter inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Synaptic vesicular amine transporter inhibitor Direct Interaction yes Trial Name Vyvanse

PMIDs: None found

Sources: TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 20002520 11861820

Sources: DrugBank

Interaction Types & Directionality: inducer (activating)

Interaction Info:

PMIDs: 7751968

Sources: DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name C105, levo-amphetamine sulfate Novel drug target Established target Trial Name SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
15094323 7751968 3129549 15955613

Sources:
DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name tetrabenazine,Nitoman

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

PMIDs:
20007701 19571144 19223416 11752352 20135628 17233532

Sources:
TEND TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

Direct Interaction yes

PMIDs:
20176067 11134 574544 1438304 17559790 8525459

Sources:
DrugBank ChemblInteractions

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name NBI-98854

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True

PMIDs:
None found

Sources:
TTD DrugBank GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
13505370 13438725 11752352 17139284 17016423

Sources:
TEND TdgClinicalTrial TTD

Interaction Types & Directionality:

n/a

PMIDs:
18500382 15955613

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

PMIDs:
None found

Sources:
DrugBank ChemblInteractions

Interaction Types & Directionality:

inducer (activating)

inhibitor (inhibitory)

Interaction Info:

Trial Name SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR

Novel drug target Established target

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

PMIDs:
7751968 15955613

Sources:
TdgClinicalTrial DrugBank ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

Direct Interaction yes

Trial Name -

PMIDs:
13505370 20176067 1438304 13438725 11752352 17139284 17016423 17559790 8525459

Sources:
TEND TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
20002520 11861820

Sources:
TTD DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
17209801 9587917 15955613

Sources:
DrugBank

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Established target

Trial Name Lobeline

PMIDs:
None found

Sources:
TdgClinicalTrial TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

Direct Interaction yes

Trial Name Vyvanse

PMIDs:
None found

Sources:
TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
20002520 11861820

Sources:
DrugBank

Interaction Types & Directionality:

inducer (activating)

PMIDs:
7751968

Sources:
DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name C105, levo-amphetamine sulfate

Novel drug target Established target

Trial Name SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR

PMIDs:
23539642 7751968 9648873 21272013 15955613

Sources:
TdgClinicalTrial DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
7912402

Sources:
DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

PMIDs:
None found

Sources:
ChemblInteractions